Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 3 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Introduction | 11 | 2 |
| GBI Research Report Guidance | 12 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Market Overview | 13 | 7 |
| Introduction | 13 | 1 |
| Revenue Forecasts for the Global Kidney and Renal Disease Market | 13 | 1 |
| Revenue | 13 | 1 |
| Annual Cost of Treatment (ACT) | 14 | 1 |
| Treatment Usage Patterns | 15 | 1 |
| Diseased Population | 16 | 1 |
| Treatment Seeking Population | 17 | 1 |
| Diagnosis Population | 18 | 1 |
| Prescription Population | 19 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Geographical Landscape | 20 | 7 |
| Revenue Analysis by Geography | 20 | 1 |
| The US | 21 | 1 |
| Revenue | 21 | 1 |
| Annual Cost of Treatment | 22 | 1 |
| Top Five Countries of Europe | 23 | 1 |
| Revenue | 23 | 1 |
| Annual Cost of Treatment | 24 | 1 |
| Japan | 25 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Treatment | 26 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Therapeutic Landscape | 27 | 40 |
| Chronic Kidney Diseases Market | 27 | 1 |
| Introduction | 27 | 1 |
| Revenue | 27 | 3 |
| Annual Cost of Treatment | 30 | 1 |
| Treatment Usage Patterns | 31 | 1 |
| Diseased Population | 32 | 1 |
| Treatment Seeking Population | 33 | 1 |
| Diagnosed Population | 34 | 1 |
| Prescription Population | 35 | 1 |
| Drivers and Barriers for the Chronic Kidney Diseases Market | 36 | 1 |
| Drivers for the Chronic Kidney Disease Market | 36 | 1 |
| Increasing Prevalence of Chronic Kidney Disease | 36 | 1 |
| Increasing Treatment Options | 36 | 1 |
| Barriers for the Chronic Kidney Disease Market | 36 | 1 |
| Low Awareness and Poor Treatment Seeking Behavior | 36 | 1 |
| Renal Anemia Market | 37 | 1 |
| Introduction | 37 | 1 |
| Revenue | 37 | 3 |
| Annual Cost of Treatment | 40 | 1 |
| Treatment Usage Patterns | 41 | 1 |
| Diseased Population | 42 | 1 |
| Treatment Seeking Population | 43 | 1 |
| Diagnosed Population | 44 | 1 |
| Prescription Population | 45 | 1 |
| Drivers and Barriers for the Renal Anemia Market | 46 | 1 |
| Drivers for the Renal Anemia Market | 46 | 1 |
| Increasing Prevalence of Renal Anemia | 46 | 1 |
| Increasing Treatment Options | 46 | 1 |
| Barriers for the Renal Anemia Market | 46 | 1 |
| Low Awareness and Poor Treatment Seeking Behavior | 46 | 1 |
| Diabetic Nephropathy Market | 47 | 1 |
| Introduction | 47 | 1 |
| Revenue | 47 | 3 |
| Annual Cost of Treatment | 50 | 1 |
| Treatment Usage Patterns | 51 | 1 |
| Diseased Population | 52 | 1 |
| Treatment Seeking Population | 53 | 1 |
| Diagnosed Population | 54 | 1 |
| Prescription Population | 55 | 1 |
| Drivers and Barriers for the Diabetic Nephropathy Market | 56 | 1 |
| Drivers for the Diabetic Nephropathy Market | 56 | 1 |
| Increasing Prevalence of Diabetic Nephropathy | 56 | 1 |
| Barriers for the Diabetic Nephropathy Market | 56 | 1 |
| Low Awareness and Poor Treatment Seeking Behavior | 56 | 1 |
| Acute Kidney Injury Market | 57 | 1 |
| Introduction | 57 | 1 |
| Revenue | 58 | 2 |
| Annual Cost of Treatment | 60 | 1 |
| Treatment Usage Patterns | 61 | 1 |
| Diseased Population | 62 | 1 |
| Treatment Seeking Population | 63 | 1 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 65 | 1 |
| Drivers and Barriers for the Acute Kidney Injury Market | 66 | 1 |
| Drivers for the Acute Kidney Injury Market | 66 | 1 |
| Increasing Prevalence of Acute Kidney Injury (AKI) | 66 | 1 |
| Increasing Diagnostic Options Biomakers: Proteomic Analysis | 66 | 1 |
| Barriers for the Acute Kidney Injury Nephropathy Market | 66 | 1 |
| Low Awareness and Poor Treatment Seeking Behavior | 66 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Product Pipeline Analysis | 67 | 26 |
| Introduction | 67 | 1 |
| Research and Development Pipeline Chronic Kidney Disease (CKD) | 68 | 6 |
| Research and Development Pipeline Renal Anemia (RA) | 74 | 2 |
| Research and Development Pipeline Diabetic Nephropathy (DN) | 76 | 3 |
| Research and Development Pipeline Acute Kidney Injury (AKI) | 79 | 3 |
| Profiles of Promising Drugs in the Kidney and Renal Disease Market | 82 | 1 |
| AMG 223 | 82 | 1 |
| Overview | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| Clinical Study Details | 82 | 1 |
| AST-120 | 83 | 1 |
| Overview | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| Clinical Study Details | 83 | 1 |
| CellCept | 84 | 1 |
| Overview | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| Clinical Study Details | 84 | 1 |
| Ferinject | 85 | 1 |
| Overview | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| Clinical Study Details | 85 | 1 |
| Genz-644470 | 86 | 1 |
| Overview | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| Clinical Study Details | 86 | 1 |
| Hematide | 87 | 1 |
| Overview | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| Clinical Study Details | 87 | 1 |
| HEPLISAV | 87 | 1 |
| Overview | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| Clinical Study Details | 87 | 1 |
| Heptar | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Clinical Study Details | 88 | 1 |
| SBR759 | 89 | 1 |
| Overview | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| Clinical Study Details | 89 | 1 |
| Sulodexide | 90 | 1 |
| Overview | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| Clinical Study Details | 90 | 1 |
| YM533 | 90 | 1 |
| Overview | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| Clinical Study Details | 90 | 1 |
| Zuragen | 91 | 1 |
| Overview | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| Clinical Study Details | 91 | 1 |
| Olmetec | 91 | 1 |
| Overview | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| Clinical Study Details | 92 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Competitive Landscape | 93 | 11 |
| Market Share Analysis | 93 | 1 |
| Amgen Inc. | 94 | 1 |
| Company Overview | 94 | 1 |
| Business Overview | 94 | 1 |
| SWOT Analysis | 95 | 1 |
| Merck &Co., Inc. | 96 | 1 |
| Company Overview | 96 | 1 |
| Business Overview | 96 | 1 |
| SWOT Analysis | 97 | 1 |
| Bristol-Myers Squibb Company | 98 | 1 |
| Company Overview | 98 | 1 |
| Business Overview | 98 | 1 |
| SWOT Analysis | 99 | 1 |
| Hoffmann-La Roche Inc. | 100 | 1 |
| Company Overview | 100 | 1 |
| Business Overview | 100 | 1 |
| SWOT Analysis | 101 | 1 |
| Shire Inc. | 102 | 1 |
| Company Overview | 102 | 1 |
| Business Overview | 102 | 1 |
| SWOT Analysis | 103 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - M&A Landscape | 104 | 10 |
| M&A Deals | 104 | 1 |
| Deal Summary | 105 | 1 |
| SICOR Pharmaceuticals reacquired the US Rights of Calcitriol from AAIPharma in 2004 | 105 | 1 |
| Amgen Acquired Ilypsa for $420m in 2007 | 105 | 1 |
| Takeda Pharmaceuticals acquired TAP Pharmaceutical from Abbott Laboratories in 2008 | 105 | 1 |
| Akela Pharma merged with Nventa Biopharmaceuticals in 2009 | 105 | 1 |
| Astellas Pharma acquired assets and rights of Diannexin from Pharmaceutical Product in 2010 | 105 | 1 |
| GlaxoSmithKline acquired additional 8.3% Stake in JCR Pharmaceuticals in 2010 | 106 | 1 |
| North Country Health Services merged with Sanford Health in 2010 | 106 | 1 |
| SolAmor Hospice acquired Countryside Hospice from High Street Capital in 2010 | 106 | 1 |
| Deals by Geography | 107 | 1 |
| Licensing Deals | 108 | 1 |
| Summary of Licensing Deals (2009-2010) | 109 | 1 |
| Kureha entered into licensing agreement with Mitsubishi Tanabe in 2009 | 109 | 1 |
| Reata Pharmaceuticals entered into licensing agreement with Kyowa Hakko Kirin in 2010 | 109 | 1 |
| Quark Pharmaceuticals entered into option licensing agreement with Novartis Pharmaceuticals for QPI-1002 in 2010 | 110 | 1 |
| Co-development Deals | 111 | 1 |
| Summary of Co-development Deals (2009-2010) | 112 | 1 |
| GlaxoSmithKline entered into an agreement with Concert Pharmaceuticals in 2009 | 112 | 1 |
| Nanomi entered into co-development agreement with Consortium in 2009 | 112 | 1 |
| Abbott entered into an agreement with Reata Pharmaceuticals in 2010 | 112 | 1 |
| Eli Lilly entered into co-development agreement with Boehringer Ingelheim in 2011 | 113 | 1 |
| Kidney and Renal Diseases Therapeutics Market to 2017 - Appendix | 114 | 5 |
| Market Definitions | 114 | 1 |
| Abbreviations | 114 | 1 |
| Research Methodology | 115 | 3 |
| Coverage | 115 | 1 |
| Secondary Research | 116 | 1 |
| Primary Research | 116 | 1 |
| Expert Panel Validation | 117 | 1 |
| Contact Us | 118 | 1 |
| Disclaimer | 118 | 1 |
| Sources | 118 | 1 |